Responses
Regular and young investigator award abstracts
Novel single-agent immunotherapies
687 Enhancement of anti-tumor immunity by ICT01: a novel g9d2 T cell-activating antibody targeting butyrophilin-3A (BTN3A)
Compose a Response to This Article
Other responses
No responses have been published for this article.